Dr. Nesrin Aslan - Neolife Tıp Merkezi
Randevu Al Bizi Arayın+90 212 385 31 00

Dr. Nesrin Aslan

Dr. Nesrin Aslan

Nükleer Tıp Uzmanı / Başhekim / İşletme Müdürü


1995 – 1999    Osmangazi Üniversitesi Tıp Fakültesi Nükleer Tıp Bölümü

1986 – 1992    Anadolu Üniversitesi Tıp Fakültesi

İş Deneyimi

2011 – Halen     Neolife Tıp Merkezi Nükleer Tıp Uzmanı / Başhekim / İşletme Müdürü

2007 – 2011       Koşuyolu Yüksek İhtisas Eğ. ve Araşt. Hastanesi Nükleer Tıp Bölümü

1999 – 2007       Acıbadem Kadıköy Hastanesi Nükleer Tıp Bölümü

Mesleki Eğitimler

2014      JCI Kalite Yönetim Sistemi

2011      Hastane Yöneticiliği Sertifika Programı (SIEMENS Akademi)

2005      ISO Kalite Sistem Yönetimi


Türkiye Nükleer Tıp Derneği



Bilimsel Çalışmalar

  1. Is there a cut-off value for standardized uptake values in positron emission tomography for predicting response to treatment and survival in patients with advanced non-small cell lung cancer? Single center experience. Oven Ustaalioglu BB, Gumus M, Bilici A, Seker M, Ustaalioglu R, Kefeli U, Salepci T, Canpolat N, Mayadagli A, Dogusoy. J BUON. 2010 Jul-Sep;15(3):529-36.
  2. The role of (18)F-FDG PET/CT in the assessment of suspected recurrent gastric cancer after initial surgical resection: can the results of FDG PET/CT influence patients’ treatment decision making? Bilici A, Ustaalioglu BB, Seker M, Kefeli U, Canpolat N, Tekinsoy B, Ozugur S, Gumus M. Eur J Nucl Med Mol Imaging. 2010 Sep 14.
  3. Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management? Bilici A, Ustaalioglu BB, Seker M, Canpolat N, Tekinsoy B, Salepci T, Gumus M. Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1259-69. Epub 2010 Mar 23.
  4. F-18 FDG PET/CT imaging in recurrent mantle cell lymphoma presenting with cauda equina syndrome.Bilici A, Ustaalioglu BB, Seker M, Canpolat N, Gumus M.Clin Nucl Med. 2010 Mar;35(3):211-2.
  5. The role of PET-CT in the differential diagnosis of thymic mass after treatment of patients with lymphoma.Ustaalioglu BB, Seker M, Bilici A, Canpolat N, Yıldirim E, Kefeli U, Ustaalioglu R, Yilmaz BE, Salepci T, Ozdemir N, Gumus M. Med Oncol. 2010 Feb 13
  6. Primary non-Hodgkin lymphoma of cervix successfully treated with rituximab: positron emission tomography images before and after therapy: a case report. Ustaalioglu BB, Bilici A, Seker M, Canpolat N, Ozdemir N, Salepci T, Gumus M.Leuk Res. 2010 Apr;34(4):e108-10. Epub 2009 Nov 20.
  7. Extended rituximab schedules may result in increased efficacy in pulmonary malt lymphoma.Seker M, Bilici A, Ustaalioglu BO, Salman T, Sonmez B, Canpolat NA, Salepci T, Gumus M, Yaylaci M. Leuk Res. 2009 Sep;33(9):e154-6. Epub 2009 Apr 21.
  8. Lesion detectability and clinical effectiveness of dual-head coincidence gamma camera imaging in comparison with dedicated PET systems in tumour patients.Narin Y, Urhan M, Canpolat N, Vardereli E, Bayhan H.J Int Med Res. 2007 Jul-Aug;35(4):467-73.
Online Randevu Doktorunuza Sorun